Espada Dermatology, a subsidiary of Mission Pharmacal Company, has acquired the GlyDerm line of skin care products from Lautus Pharmaceuticals, LLC, boosting its dermatological drug portfolio.
GlyDerm's full-potency glycolic acid offerings that use an esterification process will join Espada's existing products from Mission Dermatology and the Brava Pharma Sales Group, which are formulated to treat dry, itchy skin, acne and dermatitis.The move crates a strong anti-aging position for the company.
To highlight the acquisition, Espada will launch an educational campaign aimed at consumers and healthcare providers.
"This acquisition demonstrates Mission's focus and commitment to dermatology and skin health," said Terry Herring, president, commercial operations of Mission. "We look forward to partnering with healthcare providers in the growth and expansion of esthetic dermatology and improving the care and treatment of patients. We are excited to offer GlyDerm, a product with a proven track record in esthetic dermatology and skin health."
The company has appointed Trey Schutz as vice president, general manager, Mission Dermatology, to support the acquisition. Schutz will oversee a product portfolio of dermatology products that have both a prescription and consumer focus. He will work with David Kinnard, who will continue to oversee the sales and marketing efforts for the Mission and Brava Dermatology teams. On the consumer side of Mission Dermatology, Schutz will work with Steve Bosacki, executive director, Dermatology Consumer Esthetics.
"I am pleased to join Mission as we further expand the company's dermatological offerings," said Schutz."It is also exciting to have this talented team of existing Mission Dermatology experts and new leaders with their own pharmaceutical experiences. Together we believe the addition of Espada and the GlyDerm consumer product line to what Mission Dermatology already offers in terms of high quality prescription products will ultimately offer new levels of patient care and combined success. Our intent is to bring our collective experiences and long-lasting physician relationships to strengthen the program and its commitment to skin health innovation."
